Lantern Pharma (NasdaqCM:LTRN) Update / Briefing November 20, 2025 04:30 PM ET Speaker1Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar. We'll be talking in depth today with some of our Lantern Pharma team and also with our collaborator and partner in developing the trial and some of the early science behind LP-184. Dr. Igor Astsaturov from Fox Chase is also on with us as well. I'm going to be talking about, overall, the drug, just to give everyone an overview of ...

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Lantern Pharma (NasdaqCM:LTRN) Q3 2025 Earnings Call November 13, 2025 09:00 AM ET Company ParticipantsPanna Sharma - CEODavid Margrave - CFOOperatorMorning and welcome to our third quarter 2025 earnings call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode. We will open the call for questions and answers after our management's presentation. A webcast replay of today's conference call will be available on our website at lanternpharma.com shortly after the call. We iss ...

Lantern Pharma (NasdaqCM:LTRN) Q3 2025 Earnings Call November 13, 2025 09:00 AM ET Company ParticipantsPanna Sharma - CEODavid Margrave - CFOOperatorMorning and welcome to our third quarter 2025 earnings call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode. We will open the call for questions and answers after our management's presentation. A webcast replay of today's conference call will be available on our website at lanternpharma.com shortly after the call. We iss ...

Financial Data and Key Metrics Changes - R&D expenses decreased to approximately $2.4 million in Q3 2025 from $3.7 million in Q3 2024, primarily due to reductions in clinical trial support and consulting expenses [35] - General and administrative expenses increased to approximately $1.9 million in Q3 2025 from $1.5 million in the prior year, attributed to higher business development and investor relations costs [35] - The net loss for Q3 2025 was approximately $4.2 million, or $0.39 per share, compared to a net loss of approximately $4.5 million, or $0.42 per share in Q3 2024 [36] Business Line Data and Key Metrics Changes - The LP-184 phase 1a clinical trial achieved a 48% clinical benefit rate in evaluable cancer patients, validating the AI-driven precision medicine approach [5][11] - Preliminary phase II data from the LP-300 Harmonic trial showed an 86% clinical benefit rate, with one patient demonstrating a durable complete response for nearly two years [20][21] - The LP-284 program targeting recurrent non-Hodgkin's lymphoma generated interest from biopharma companies, showcasing a complete metabolic response in a heavily pretreated patient [23] Market Data and Key Metrics Changes - The combined annual market potential for the targeted indications of LP-184 exceeds $7 billion, with specific opportunities in triple-negative breast cancer, non-small cell lung cancer, bladder cancer, and recurrent GBM [17] - The market opportunity for the LP-300 program in lung cancer among never-smokers is approaching $4 billion annually, with no current approved therapies for this demographic [19] - The LP-284 program has a global market opportunity of about $3 billion, focusing on patients with aggressive recurrent non-Hodgkin's lymphoma [22] Company Strategy and Development Direction - The company is focused on integrating AI and machine learning into drug discovery and development, positioning itself as a leader in precision oncology [4][39] - The RADR AI platform is being commercialized, with eight distinct AI-powered modules developed to address critical pain points in oncology drug development [26][34] - The introduction of the Zeta platform aims to streamline rare cancer research and drug development, enhancing decision-making and reducing costs [30][32] Management's Comments on Operating Environment and Future Outlook - Management highlighted the transformative nature of the past quarter, achieving significant clinical, regulatory, and validation milestones [5] - The company expects to continue advancing its clinical assets while scaling its AI platform for commercial deployment, emphasizing a dual engine strategy [39][40] - Management expressed confidence in the potential of their AI tools and services to represent several hundred million dollars in standalone market potential [34] Other Important Information - As of September 30, 2025, the company had approximately $12.4 million in cash, cash equivalents, and marketable securities, providing a runway into approximately Q3 2026 [36] - The company entered into an ATM sales agreement to offer and sell up to $15.53 million of its common stock, raising approximately $989,000 during Q3 2025 [37] Q&A Session Summary Question: Update on interim event analysis for the LP-300 trial - Management indicated that they do not expect to reach the 31 events required for analysis until early 2026, which is seen as positive news as it suggests patients are remaining on the trial longer [41] Question: Status of the Denmark trial - The Denmark trial has been approved, with IRBs set and a project manager assigned, expected to start in late December or early January [42] Question: IND submission for the pediatric CNS program - Management confirmed readiness to submit the IND for the pediatric CNS program in the coming weeks [42] Question: Details on the Zeta platform - The Zeta platform is expected to have an interesting and bumpy early rollout, with internal usage already underway and plans for broader rollout in Q1 [43] Question: Indications for LP-184 - Management plans to identify the most impactful indications for larger scale trials, with interest from pharmaceutical companies [44]

Third Quarter 2025 Operating & Financial Results Conference Call / Webinar Nov 13th, 2025 9AM Eastern Time NASDAQ :LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of o ...

Clinical Trials and Drug Development - LP-184 Phase 1a clinical trial achieved a 48% clinical benefit rate in evaluable cancer patients at or above the therapeutic dose threshold, with marked tumor reductions in patients with specific DNA damage repair mutations[2] - The FDA Type C meeting provided regulatory guidance for Starlight Therapeutics' planned pediatric CNS cancer trial, confirming the combination strategy with spironolactone[8] - LP-300 Phase 2 HARMONIC™ trial is ongoing, evaluating the drug in combination with standard chemotherapy for NSCLC patients who have progressed after TKI therapy[10] - The Company plans to initiate a Pediatric CNS cancer trial in Q1 2026 and LP-184 Phase 1b/2 trials in TNBC and NSCLC, subject to funding[29] - Lantern Pharma's AI platform, RADR, utilizes over 200 billion oncology-focused data points to enhance drug discovery and development efficiency[30] - The Company will host a KOL scientific webinar on November 20, 2025, to discuss LP-184 Phase 1a results and clinical development strategy[29] Financial Performance - Lantern Pharma has approximately $12.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025, down from approximately $24.0 million at the end of 2024, providing an operating runway into approximately Q3 2026[20] - R&D expenses decreased to approximately $2.4 million for Q3 2025, compared to approximately $3.7 million for Q3 2024, primarily due to reductions in research studies and materials[21] - General and Administrative expenses increased to approximately $1.9 million for Q3 2025, up from approximately $1.5 million for Q3 2024, driven by higher business development and investor relations expenditures[22] - Net loss for Q3 2025 was approximately $4.2 million (or $0.39 per share), compared to a net loss of approximately $4.5 million (or $0.42 per share) for Q3 2024[23] - Operating expenses for Q3 2025 totaled $4,349,800, a decrease from $5,179,576 in Q3 2024, indicating a 16% reduction year-over-year[40] - The net loss for Q3 2025 was $4,177,423, compared to a net loss of $4,505,697 in Q3 2024, showing a 7% improvement[40] - As of September 30, 2025, total current assets decreased to $13,461,005 from $25,247,629 as of December 31, 2024, reflecting a significant reduction[38] - The Company reported a cash and cash equivalents balance of $8,389,486 as of September 30, 2025, up from $7,511,079 at the end of 2024[38] - The weighted-average number of common shares outstanding for Q3 2025 was 10,833,393, slightly increasing from 10,763,351 in Q3 2024[40] Strategic Initiatives - The Company entered into an ATM Sales Agreement allowing the sale of up to $15,530,000 of common stock, with $989,061 raised from 212,444 shares sold in Q3 2025[25] - Lantern Pharma expects to scale up commercial efforts for its AI platform and prepare for potential capital formation activities to support clinical advancements in 2026[29] - The RADR AI platform demonstrated a 94.1% accuracy for blood-brain barrier permeability prediction, addressing a critical pharmaceutical challenge[18] - LP-284 has received multiple FDA Orphan Drug Designations, highlighting its potential in treating aggressive lymphomas[14] - The company is advancing development plans for LP-184 in high-value indications, with a combined market potential exceeding $7 billion annually[2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS ...

Lantern Pharma Conference Call Summary Company Overview - **Company**: Lantern Pharma (NasdaqCM: LTRN) - **Focus**: AI-driven drug development, particularly in oncology, utilizing proprietary AI platforms to identify and develop targeted therapies [1][2] Key Points and Arguments AI and Drug Development - Lantern Pharma has developed **12 drug programs** since late 2018, with **three currently in clinical trials** [2] - The company emphasizes the use of AI to accelerate drug discovery, aiming to make the process faster and more cost-effective [2][3] - The AI platform has evolved significantly, reducing the time to update and improve its capabilities from over a year to less than four months [6][16] Clinical Trials and Drug Candidates - **LP-300**: Targeting lung cancer in non-smokers, currently in Phase 2 trials. This demographic represents about **17% of lung cancer cases in the U.S.** and **35-40% in East Asia** [5][27] - **LP-284**: A drug for non-Hodgkin's lymphoma showing complete metabolic response in trials. It is positioned as a potential blockbuster with a market potential of over **$10 billion** [6][31] - **LP-184**: Targets cancers with DNA damage repair deficiencies, with a market potential of over **$4 billion**. It has shown promising results in various cancers, including lung and triple-negative breast cancer [32][27] Business Model and Market Strategy - Lantern Pharma's business model includes repositioning existing drugs and developing new ones, with a focus on precision oncology [4][9] - The company plans to monetize its AI platform through a **freemium model**, allowing other cancer drug developers to access its technology [7][19] - The company is also preparing to spin out **Starlight Therapeutics**, focusing exclusively on brain cancers, which could enhance its market valuation [11][12] Financials and Market Position - As of the last quarter, Lantern Pharma reported approximately **$15.9 million** in cash with a burn rate of **$4 to $4.5 million** per quarter [36] - The company has not raised capital since January 2021 and has no toxic financial events or warrants [36] Regulatory Environment - The FDA is increasingly focusing on AI models in drug development, which could benefit Lantern Pharma's initiatives, especially in pediatric cancers [36][37] - Lantern has received multiple rare pediatric designations, enhancing its potential for market success [37] Additional Important Insights - The company is actively engaging with pharmaceutical companies for potential partnerships, although challenges exist due to industry skepticism towards AI [21][22] - Lantern Pharma's approach to drug development is characterized by a willingness to explore multiple avenues simultaneously, reflecting a strategy to mitigate risks in a highly uncertain field [24][26] - The company believes that the future of medicine will increasingly rely on AI, positioning itself as a leader in this transformative space [27] This summary encapsulates the critical aspects of Lantern Pharma's conference call, highlighting its innovative approach to drug development, clinical advancements, and strategic positioning in the oncology market.

Core Insights - Lantern Pharma presented clinical data for LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma Congress, showcasing a complete metabolic response in a patient with aggressive DLBCL who had previously failed multiple therapies [1][3][4] - The drug LP-284 demonstrates potential as both a monotherapy and a combination therapy, addressing a significant market need in post-immunotherapy settings for patients with relapsed or refractory B-cell cancers [2][5][6] Clinical Data Presentation - A 41-year-old patient with Grade 3 DLBCL achieved a complete metabolic response after two cycles of LP-284, administered intravenously [2][4] - The patient had extensive bony lesions and had previously failed treatments including CAR-T and bispecific antibody therapies [2][4] Mechanism of Action - LP-284 operates through a novel synthetic lethal mechanism targeting DNA repair deficiencies, which allows it to be effective regardless of TP53 mutation status [4][11] - The drug has shown preclinical synergy with FDA-approved therapies, particularly with rituximab, enhancing its potential for combination treatments [4][9][11] Market Opportunity - DLBCL is the most common aggressive non-Hodgkin's lymphoma subtype, with around 200,000 new cases diagnosed globally each year, highlighting the critical need for effective treatments in this area [6][7] - LP-284 targets a market estimated at $3-4 billion annually for relapsed/refractory B-cell cancers, addressing both clinical and economic burdens [4][7] Development and Partnerships - Lantern Pharma is actively engaging with biopharmaceutical companies for potential partnerships, focusing on LP-284's use in combination regimens with existing therapies [9][14] - The ongoing Phase 1a study continues to evaluate LP-284's safety and efficacy, with favorable early results indicating a well-tolerated profile [8][12] Strategic Positioning - The company has received multiple FDA Orphan Drug Designations for LP-284, providing regulatory advantages and commercial exclusivity [11][15] - Lantern's RADR® AI platform is instrumental in accelerating drug development and identifying synergistic opportunities, enhancing the overall efficiency of the process [11][17]